May 29, 2024 · WTX-124 is a half-life extended, masked cytokine (INDUKINE molecule) rationally engineered to release wild type IL-2 in tumors. We previously reported that WTX-124 is clinically active as a monotherapy at doses safely administered in the outpatient setting.

May 3, 2022 · Here, we describe the design and characterization of a conditionally activated IL-2 prodrug, WTX-124, that takes advantage of the dysregulated protease milieu of tumors.

• Our work shows that WTX-124, a pro-drug containing wild-type IL-2, is selectively processed and activated in tumors and is efficacious in murine models, even in the presence of regulatory T cells • WTX-124 activity is dependent on the processing of the pro-drug as a non-cleavable version of WTX-124 (WTX-124-NC) is not efficacious in our ...

4 days ago · WTX-124: a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule being developed as monotherapy and in combination with pembrolizumab in multiple solid tumor types. Werewolf continues to evaluate WTX-124 as a monotherapy and in combination with pembrolizumab through the ongoing Phase 1/1b clinical trial ...

Nov 3, 2023 · Study WTX-124x2101 is evaluating WTX-124 as a monotherapy and in combination with pembrolizumab in patients with immunotherapy sensitive advanced or metastatic solid tumors who have failed standard of care treatment, including checkpoint inhibitor therapy.

4 days ago · Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a ...

May 3, 2022 · WTX-124, an IL-2 containing INDUKINE protein, was designed to enhance the clinical profile of rhIL-2 treatment by facilitating less frequent systemic delivery, increasing the tumor exposure of the molecule, and decreasing the toxicity associated with high-dose IL-2.

WTX-124 exhibits approximately dose-proportional PK with very low levels of active IL-2 (<1% of prodrug). Tumor biopsies are being analyzed for changes in the frequency and functionality of tumor-infiltrating lymphocytes, PD-L1 expression, and immune cell gene expression.

Jun 15, 2022 · To address these limitations, we designed WTX-124, an IL-2 pro-drug (IL-2 INDUKINE™ protein) that takes advantage of dysregulated protease activity in the tumor microenvironment (TME) to selectively release active IL-2 in …

The company investigating WTX-124, a conditionally activated interleukin-2 (IL-2) based drug to treat multiple tumor types and WTX-330 and WTX-613 drugs administered as monotherapies for refractory and immunologically unresponsive tumors.